Table 3.

Ongoing clinical trials of nafamostat mesylate in the treatment of COVID-19 patients

Trial registration, date posted, and location	Study title	Intervention model description	Treatment	Primary outcome measures	Participants	Status
NCT04352400 Posted April 2020 Italy	Efficacy of Nafamostat in COVID-19 Patients (RACONA Study)	Prospective, double blind, randomised, placebo-controlled parallel group, on top of best standard of care	Nafamostat administered by continuous infusion, placebo	Time to clinical improvement	256	Recruiting
NCT04390594 Posted May 2020 Senegal	Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal	Open-label, multicentre, randomised, parallel assignment	Nafamostat (0.1–0.2 mg/kg/h), standard of care	SARS-CoV-2 viral load level	186	Recruiting
JPRN-jRCTs031200026 Posted May 2020 Japan	Combination therapy of Favipiravir and Nafamostat Mesylate in Patients with COVID-19 pneumonia	Randomised controlled trial	Nafamostat, favipiravir, standard of care	Change in patient condition on a 10-point scale from baseline to day 7	160	Recruiting
NCT04418128 KCT0005003 Posted June 2020 South Korea	Clinical Efficacy of Nafamostat Mesylate for COVID-19 Pneumonia	Open-label, randomised, parallel assignment	Nafamostat (0.1–0.2 mg/kg/h by continuous infusion), conventional therapy	Proportion of patients with clinical improvement	84	Not yet recruiting
NCT04483960 ACTRN12620000445976 Posted July 2020 Australia	Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial (ASCOT ADAPT)	Open-label, international multicentre, randomised	Nafamostat (0.2 mg/kg/h by continuous infusion), hyperimmune globulin, enoxaparin, dalteparin, tinzaparin	Death or requirement of new intensive respiratory support (invasive or non-invasive ventilation) or vasopressor/inotropic support	2400 (estimated)	Recruiting
CTRI/2020/06/026220 Posted July 2020 India	A study to evaluate the efficacy and safety of Nafamostat Mesylate in treatment of Coronavirus infection	Open-label, multicentre, randomised, parallel/crossover assignment	Nafamostat (0.1 mg/kg/h for 24 h by continuous infusion for 10 days), standard of care	Proportion of patients showing clinical improvement by day 14	40	Completed
NCT04628143 Posted November 2020 South Korea	A Study Evaluating the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia	Open-label, multicentre, randomised, parallel assignment	Nafamostat administered by continuous infusion, standard of care	Time to clinical improvement	13	Completed
JPRN-jRCTs031210183 Posted July 2021 Japan	Exploratory research of nafamostat mesylate in early mild COVID-19 patients	Open-label, randomised, parallel assignment	Nafamostat (0.1 or 0.2 mg/kg/h for 6 days), standard treatment	AUC of SARS-CoV-2 virus reduction in the nasopharynx from before the start of treatment to the 6th day of treatment	30	Recruiting

COVID-19 coronavirus disease 2019, SARS-CoV-2 severe acute respiratory syndrome coronavirus-2